TY - JOUR T1 - Minimizing school disruption under high incidence conditions due to the Omicron variant in early 2022 JF - medRxiv DO - 10.1101/2022.02.04.22270473 SP - 2022.02.04.22270473 AU - Elisabetta Colosi AU - Giulia Bassignana AU - Alain Barrat AU - Bruno Lina AU - Philippe Vanhems AU - Julia Bielicki AU - Vittoria Colizza Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270473.abstract N2 - As record cases due to the Omicron variant are currently registered in Europe, schools remain a vulnerable setting suffering large disruption. Extending previous modeling of SARS-CoV-2 transmission in schools in France, we estimate that at high incidence rates reactive screening protocols (as currently applied in France) require comparable test resources as weekly screening (as currently applied in some Swiss cantons), for considerably lower control. Our findings can be used to define incidence levels triggering school protocols and optimizing their cost-effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by: ANR projects COSCREEN (ANR-21-CO16-0005) and DATAREDUX (ANR-19-CE46-0008-03); ANRS-MIE project EMERGEN (ANRS0151); EU H2020 grants MOOD (H2020-874850) and RECOVER (H2020-101003589); EU HORIZON grant VERDI (101045989); REACTing COVID-19 grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -